Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatr Hematol Oncol 2017 Sep - Oct;34(6-7):355-364

Date

12/01/2017

Pubmed ID

29190164

Pubmed Central ID

PMC6191173

DOI

10.1080/08880018.2017.1395937

Abstract

During the 2016 Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium investigators' meeting (Los Angeles, CA), a Biology Working Group was established to support the consortium's mission of developing innovative therapies for currently incurable childhood leukemias and lymphomas. The charge of the Biology Working Group was to address how TACL could advance biological investigations of pediatric relapsed/refractory hematologic malignancies while undertaking forward-looking therapeutic trials. To this end, the TACL Biology Committee was established to provide the scientific platform needed to further develop preclinical and translational studies that will advance the understanding and treatment of relapsed and refractory disease. The Biology Committee will focus on ensuring state-of-the-art studies that address biological components of early phase clinical trials, and developing a central biology bank of materials from these early phase trials for interrogations into the mechanisms of disease resistance.

Author List

Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH

Author

Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Acute Disease
Adolescent
Child
Child, Preschool
Congresses as Topic
Female
Humans
Infant
Infant, Newborn
Leukemia
Lymphoma
Male
Recurrence
Translational Medical Research
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a